{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-024313","form_type":"8-K","ticker":"FEMY","cik":"0001339005","company_name":"FEMASYS INC","filed_at":"2025-07-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.772672+00:00","generated_at":"2026-05-18T09:55:19.968725+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Femasys gets Australian & New Zealand approvals for FemaSeed and FemVue","bullets":["Regulatory approvals granted for FemaSeed first-line intratubal insemination treatment and FemVue diagnostic.","CEO Kathy Lee-Sepsick cites expanded global access and meaningful commercial opportunities.","Approvals validate clinical value of platform and reinforce commitment to accessible infertility solutions.","Company expects to grow revenue and broaden global footprint with these regulatory milestones."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-024313","json":"https://secwatch.observer/filing/0001140361-25-024313.json","markdown":"https://secwatch.observer/filing/0001140361-25-024313.md","text":"https://secwatch.observer/filing/0001140361-25-024313.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1339005/000114036125024313/0001140361-25-024313-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1339005/000114036125024313/ef20051434_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T09:55:19.968725+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}